A dorsal subcutaneous mass was excised from an 18-yr-old female lion. Histopathology revealed spindle cell sarcoma with necrotic center, high mitotic index, and narrow surgical margins. Similar tumors have been reported in other non-domestic felids.7,9,12 A continuous, oral, metronomic, antiangiogenic chemotherapeutic protocol was initiated post-operatively: cyclophosphamide (Roxane Laboratories, Columbus, OH) 25 mg/m2 PO EOD, piroxicam (TEVA Pharmaceuticals, Sellersville, PA) 0.27 mg/kg PO SID, and doxycycline (West-ward Pharmaceutical Corp. Eatontown, NJ) 4.5 mg/kg PO BID. Periodic urinalyses, complete blood counts, and chemistry panels were monitored for evidence of side effects. The surgical site healed without significant complications. The lion was euthanatized 7.5 mo post-operatively for disease unrelated to the tumor; no neoplasia was identified on gross or microscopic evaluation.
In domestic cats, a combination of aggressive surgical excision, radiation therapy, +/- intravenous chemotherapeutics is the recommended treatment for soft tissue sarcomas; recurrence with local invasiveness is common although metastasis is relatively rare.4,5,10 Metronomic antiangiogenic chemotherapy uses chronic administration of chemotherapeutic agents at low, minimally toxic doses with no drug-free breaks to overcome drug resistance by shifting the therapeutic target from tumor cells to tumor vasculature.11,13 Metronomic protocols incorporating oral cyclophosphamide and piroxicam have shown promise for treatment of sarcomas in domestic dogs; doxycycline has demonstrable antiangiogenic properties.1,2,8,14 Metronomic antiangiogenic therapy has not been previously reported in Panthera species and warrants further evaluation for management of neoplasia in carnivores. If effective, it could improve outcome while minimizing anesthetic events and undesirable side effects associated with chemotherapy.3,6
The authors thank the staff of the Departments of Animal Health, Pathology, and Animal Care at the Smithsonian Institution’s National Zoological Park for assistance with this case.
1. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med. 2008;22:1373–1379.
2. Fife RS, Sledge GW, Sissons S, Zerler B. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett. 2000;153:75–78.
3. Ganjoo K, Jacobs C. Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer. 2010;116:1177–1183.
4. Hahn LA, Endicott MM, King GK, Harris-King FD. Evaluation of radiotherapy alone or in combination with doxorubicin chemotherapy for the treatment of cats with incompletely excised soft tissue sarcomas: 71 cases (1989–1999). J Am Vet Med Assoc. 2007;231:742–745.
5. Hauck M. Feline injection site sarcomas. Vet Clin North Am Small Anim Pract. 2003;33:553–557.
6. Hwang RF, Hunt KK. Experimental approaches to treatment of soft tissue sarcoma. Surg Oncol Clin N Am. 2003;12:499–521.
7. Kinne J, Tarello W. Vaccine-associated fibrosarcoma in a lion (Panthera leo). Revue Med Vet. 2007;158:73–74.
8. Lana S, U’ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007;21:764–769.
9. Larsen RS, Carpenter JW. Suspected vaccine- and/or dart-associated fibrosarcoma in a tiger (Panthera tigris). Verh ber Erkrg Zootiere. 1999;39:401–404.
10. Martano M, Morello E, Buracco P. Feline injection-site sarcoma: past, present, and future perspectives. Vet J. 2011;188:136–141.
11. Mutsaers AJ. Metronomic chemotherapy. Top Companion Anim Med. 2009;24:137–143.
12. Ofendaal JS, Van der Merwe SJ, Coetzee FP, Botha WS. Subcutaneous fibrosarcoma in a lion (Panthera leo). Abstr J S Afr Vet Assoc. 1985;56:143–144.
13. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–465.
14. Yau JS, Shen F, Young WL, Yang GY. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int. 2007;50:524–530.